PERTH, Australia – Sydney-based Minomic International Ltd.'s Micheck prostate cancer diagnostic was more than twice as specific in screening for prostate cancer than the standard of care prostate specific antigen (PSA) screening technology, a recent clinical trial showed. The Micheck diagnostic met both primary endpoints in a U.S. multicenter trial in 384 patients. The trial was a prospective, non-randomized case-control study, with a primary endpoint of detecting prostate cancer versus no cancer, and a secondary endpoint of differentiating between aggressive and non-aggressive cancer.
PERTH, Australia – Industry stakeholders praised Australia's federal budget for 2018-2019, released late last week, because the government said it was seeing results from investments pumped into the medical technology and pharmaceuticals sector, and it will continue to invest more.
PERTH, Australia – Industry stakeholders praised Australia's federal budget for 2018-2019, released late last week, because the government said it was seeing results from investments pumped into the medical technology and pharmaceuticals sector, and it will continue to invest more.
PERTH, Australia – Melbourne-based Starpharma Holdings Ltd. has entered a sales and marketing deal with Mundipharma International Ltd., which gives Mundipharma sales and marketing rights to Vivagel BV for bacterial vaginosis (BV) in Asia, the Middle East, Africa and the majority of Latin America.
PERTH, Australia – Melbourne-based Starpharma Holdings Ltd. has entered a sales and marketing deal with Mundipharma International Ltd., which gives Mundipharma sales and marketing rights to Vivagel BV for bacterial vaginosis (BV) in Asia, the Middle East, Africa and the majority of Latin America.
